Evaluation of immune responses and protection induced by A2 and nucleoside hydrolase (NH) DNA vaccines against Leishmania chagasi and Leishmania amazonensis experimental infections

Zanin, Francisca Helena Calheiros; Coelho, Eduardo Antônio Ferraz; Tavares, Carlos Alberto Pereira; Silva, Eduardo de Almeida Marques da; Costa, Murilo Soares; Rezende, Simone Aparecida; Gazzinelli, Ricardo T.; Fernandes, Ana Paula

doi:10.1016/j.micinf.2007.05.012

Cited by 68 publications

(61 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Gomes et al (2007) showed that, after intranasal immunization with a plasmid expressing the Leishmania analogue of the receptors of activated C kinase, BALB/c mice developed lower parasite burdens and had a decrease in IL-10 production. In another study, it was shown that BALB/c mice immunized with a plasmid encoding the A2 gene were protected against experimental challenge with L. amazonensis or L. donovani and that this protection was associated with a reduced level of IL-10 production (Zanin et al 2007). Finally, it is already known that human VL is associated with high levels of IL-10.…”

Section: Discussionmentioning

confidence: 97%

Antigenic extracts of Leishmania braziliensis and Leishmania amazonensis associated with saponin partially protects BALB/c mice against Leishmania chagasi infection by suppressing IL-10 and IL-4 production

Grenfell

Silva

Testasicca

et al. 2010

Mem. Inst. Oswaldo Cruz

Self Cite

View full text Add to dashboard Cite

This study evaluated two vaccine candidates for their effectiveness in protecting BALB/c mice against Leishmania chagasiinfection. These immunogenic preparations were composed of Leishmania amazonensisor Leishmania braziliensisantigenic extracts in association with saponin adjuvant. Mice were given three subcutaneous doses of one of these vaccine candidates weekly for three weeks and four weeks later challenged with promastigotes of L. chagasiby intravenous injection. We observed that both vaccine candidates induced a significant reduction in the parasite load of the liver, while the L. amazonensisantigenic extract also stimulated a reduction in spleen parasite load. This protection was associated with a suppression of both interleukin (IL)-10 and IL-4 cytokines by spleen cells in response to L. chagasiantigen. No change was detected in the production of IFN-γ. Our data show that these immunogenic preparations reduce the type 2 immune response leading to the control of parasite replication

show abstract

Section: Discussionmentioning

confidence: 97%

Antigenic extracts of Leishmania braziliensis and Leishmania amazonensis associated with saponin partially protects BALB/c mice against Leishmania chagasi infection by suppressing IL-10 and IL-4 production

Grenfell

Silva

Testasicca

et al. 2010

Mem. Inst. Oswaldo Cruz

Self Cite

View full text Add to dashboard Cite

show abstract

“…35 DNAencoding A2 protein mediated protection against L amazonensis infection in mice in contrast to heat shock protein 20 (HSP20) and surface protein 2. 49,50 More recently, the TSA-based DNA vaccine was successful in controlling L major challenge via a T H 1 immune response. 76 Iron superoxide dismutase of L donovani protected Balb/C mice against L amazonensis infection by inducing IFN-γ production which led to reduced parasitism.…”

Section: Dna Vaccinesmentioning

confidence: 99%

Cutaneous Leishmaniasis: Update on Vaccine Development

Zufferey¹,

Whyte²

2017

HPD

View full text Add to dashboard Cite

ABSTRACT:Leishmaniasis is an important disease mediated by the protozoan parasite Leishmania via the bite of the female sandfly insect vector. Leishmaniasis is endemic in the tropical and subtropical regions. The most common form of the disease is cutaneous leishmaniasis, which affects more than 10 million people worldwide and includes at least 1.5 million new cases every year. So far, treatment of the disease relies on unsatisfactory chemotherapy that can be complicated by the rising appearance of drug-resistant parasites. Furthermore, it is challenging to achieve solid control of the insect vector and animal reservoir. Therefore, the development of a safe and effective vaccine is urgently needed for the treatment and prevention of leishmaniasis. This review focuses on the recent advances in the development of a safe vaccine that could be used for prevention and treatment of cutaneous leishmaniasis. A short outlook for future research efforts is also presented.

show abstract

“…It is encoded by a multigene family that is abundantly expressed in the amastigote forms of some Leishmania species able to cause VL (40) . Studies of the administration of recombinant A2 protein associated with immune adjuvants (41) (42) or as a DNA vaccine (43) , as well as in attenuated non-replicative viruses (44) , non-pathogenic bacteria (45) , or non-virulent Leishmania tarentolae (46) , have provided evidence of its protective effi cacy in mammalian models. In general, anti-A2 protective immunity is associated with the generation of parasite-specifi c IgG2a antibodies, as well as with the production of high levels of antileishmanial IFN-γ and low levels of IL-10 by T cells in recall response to the A2 protein or parasite extracts (40) .…”

Section: Second-generation Vaccines Against Visceral Leishmaniasismentioning

confidence: 99%

Recent updates and perspectives on approaches for the development of vaccines against visceral leishmaniasis

Duarte

Lage

Martins

et al. 2016

Rev. Soc. Bras. Med. Trop.

View full text Add to dashboard Cite

Visceral leishmaniasis (VL) is one of the most important tropical diseases worldwide. Although chemotherapy has been widely used to treat this disease, problems related to the development of parasite resistance and side effects associated with the compounds used have been noted. Hence, alternative approaches for VL control are desirable. Some methods, such as vector control and culling of infected dogs, are insuffi ciently effective, with the latter not ethically recommended. The development of vaccines to prevent VL is a feasible and desirable measure for disease control; for example, some vaccines designed to protect dogs against VL have recently been brought to market. These vaccines are based on the combination of parasite fractions or recombinant proteins with adjuvants that are able to induce cellular immune responses; however, their partial effi cacy and the absence of a vaccine to protect against human leishmaniasis underline the need for characterization of new vaccine candidates. This review presents recent advances in control measures for VL based on vaccine development, describing extensively studied antigens, as well as new antigenic proteins recently identifi ed using immuno-proteomic techniques.

show abstract

Evaluation of immune responses and protection induced by A2 and nucleoside hydrolase (NH) DNA vaccines against Leishmania chagasi and Leishmania amazonensis experimental infections

Cited by 68 publications

References 28 publications

Antigenic extracts of Leishmania braziliensis and Leishmania amazonensis associated with saponin partially protects BALB/c mice against Leishmania chagasi infection by suppressing IL-10 and IL-4 production

Antigenic extracts of Leishmania braziliensis and Leishmania amazonensis associated with saponin partially protects BALB/c mice against Leishmania chagasi infection by suppressing IL-10 and IL-4 production

Cutaneous Leishmaniasis: Update on Vaccine Development

Recent updates and perspectives on approaches for the development of vaccines against visceral leishmaniasis

Contact Info

Product

Resources

About